Skip to main content
Premium Trial:

Request an Annual Quote

Saladax, CESAR Partner on Study of 5-FU Dosing for Colorectal Cancer

NEW YORK (GenomeWeb News) – Saladax Biomedical announced today a collaborative study of metastatic colorectal cancer patients treated with 5-fluorouracil, or 5-FU, and whose doses will be optimized based on actual 5-FU blood levels.

As part of the collaboration with the Central European Society for Anticancer Drug Research, or CESAR, Saladax's My5-FU immunoassay technology will be used to measure 5-FU levels.

CESAR is sponsoring the single-arm study, which is designed "to determine whether target blood levels of 5-FU can be maintained during the course of treatment by optimizing the dose administered to individual patients at each infusion," the Bethlehem, Penn.-based company said in a statement. The two partners aim to achieve a stable target blood level of the chemotherapeutic and investigate whether this dose optimization can reduce 5-FU-related toxicities.

Financial and other terms of the deal were not disclosed.

The study, which involves four centers and will enroll 80 patients with metastatic colorectal cancer, is expected to last one year. Patients will remain in the study until a total of six doses of 5-FU treatment has been administered and the end-of-treatment visit has been conducted, Saladax said.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.